As shown in Figure 2d–i, the flow cytometry results indicated that the uptake of the personalized tumor vaccines treated with the serum from the KLH-immunized mice by DCs (CD11c-positive) and Mφs (F4/80-positive) was significantly increased compared to those treated with the serum from untreated mice. The gene discussed is ITGAX; the disease is neoplasm.